Latest Content

Patients with AML receiving azacitidine and venetoclax had significantly higher quality of life than those receiving intensive induction chemotherapy.

Blinatumomab/ponatinib increased efficacy, and response rates were improved in patients with Philadelphia-positive acute lymphoblastic leukemia.

The addition of epcoritamab to R2 significantly reduced the risk of death or disease progression in patients with relapsed/refractory follicular lymphoma.

Older patients with newly diagnosed diffuse large B-cell lymphoma receiving epcoritamab plus R-mini-CHOP achieved deep responses with manageable safety.

Shifting to a higher and less frequent dose of axatilimab was tolerable and feasible in patients with chronic GVHD.

KRd demonstrated higher PFS, deeper response, and greater MRD negativity compared with VRd in newly diagnosed multiple myeloma.

The combination of odronextamab with CHOP chemotherapy showed early efficacy in patients with untreated diffuse large B-cell lymphoma.

Nearly one-third of families of children with acute lymphoblastic leukemia developed “catastrophic” financial toxicity during the patient’s treatment.

Higher LDH levels were linked with poorer survival outcomes in patients with relapsed and refractory multiple myeloma who received elranatamab.

Fixed-duration venetoclax combined with obinutuzumab or ibrutinib produced noninferior PFS compared with continuous ibrutinib monotherapy.

Race was identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

Danielle Blair, RN, BSN, OCN, CCRP, explains what her role as an adolescent and young adult nurse navigator in oncology entails.

The FDA has approved the use of lisocabtagene maraleucel in patients with relapsed/refractory marginal zone lymphoma.